Skip to content

Evaluating role of Adaptive radiotherapy in head neck cancers in reducing salivary gland toxicity

Reducing Salivary Toxicity with Adaptive Radiotherapy : A Randomized Controlled trial. - ReSTART

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/08/015531
Enrollment
130
Registered
2018-08-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

Intervention1: Experimental Arm B - A-IGRT: Head and neck cancer patients planned for curative radiotherapy with concurrent chemotherapy at Department of Radiation Oncology, Tata Memorial centre, who

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Biopsy proven Squamous cell carcinoma of the oropharynx, hypopharynx and larynx. 2.AJCC stage T1-3, N0-2c, M 0. 3.KPS >= 70. 4.Age >=18 and 5.Patient willing and reliable for follow-up. 6.Patientâ??s nutritional & physical condition compatible with planned therapy. 7.Signed study specific consent form.

Exclusion criteria

Exclusion criteria: 1.T1-2 N0 M0 of Vocal cords 2.History of surgery for the primary or node in head and neck. 3.Evidence of distant metastases or N3 nodal stage. 4.Previous therapeutic irradiation for head & neck cancer. 5.Patients who have received neoadjuvant chemotherapy. 6.Active untreated infection, which preclude the use of systemic chemotherapy or would interfere with completion of treatment. 7.Any histopathology other than Squamous Carcinoma. 8.Primary nasopharyngeal or paranasal sinus cancers. 9.Pregnancy or lactating women. 10.Previous history of malignancy within 5 years.

Design outcomes

Primary

MeasureTime frame
1.Salivary toxicity at 12 months post radiation: The acute salivary toxicity will be assessed with salivary scintigraphy. The salivary function at 12 months will be determined by the ratio of SEF at 12 months after treatment compared to the baseline SEF (pre-treatment) x 100%.Timepoint: 1 year

Secondary

MeasureTime frame
1.To assess the acute and late normal tissue toxicity. 2.To compare the loco-regional control. 3.To compare the disease free survival. 4.To compare the overall survival. 5.To compare the quality of life in patients randomized to the two study arms. 6.To assess parotid shrinkage over time and document the dosimetric changes.Timepoint: 1, 3 , 5 yrs

Countries

India

Contacts

Public ContactDr Sarbani Ghosh Laskar

Tata Memorial Hospital

sarbanilaskar@gmail.com9820834386

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026